Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion

Yi-Wen Shi, Rui-Xu Yang, Jian-Gao Fan, Yi-Wen Shi, Rui-Xu Yang, Jian-Gao Fan

Abstract

With the increasing incidence of obesity and metabolic syndrome worldwide, concomitant nonalcoholic fatty liver disease (NAFLD) in patients with chronic hepatitis B (CHB) has become highly prevalent. The risk of dual etiologies, outcome, and mechanism of CHB with concomitant NAFLD have not been fully characterized. In this review, we assessed the overlapping prevalence of metabolic disorders and CHB, assessed the risk of advanced fibrosis/hepatocellular carcinoma in CHB patients concomitant with NAFLD, and discussed the remaining clinical issues to be addressed in the outcome of such patients. We also explored the possible roles of hepatitis B virus in the development of steatosis and discussed difficultiesof histological evaluation. For CHB patients, it is important to address concomitant NAFLD through lifestyle management and disease screening to achieve better prognoses. The assessment of progressive changes and novel therapies for CHB patients concomitant with NAFLD deserve further research.

Keywords: Disease burden; Hepatitis B; Mechanism; Metabolic disorders; Nonalcoholic fatty liver disease; Steatosis.

Conflict of interest statement

Conflict-of-interest statement: The authors declare that theyhaveno competinginterests.

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Figures

Figure 1
Figure 1
Meta-analysis of the prevalence of hepatic steatosis in patients with hepatitis B virus infectionvs control.

References

    1. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403. doi: 10.1016/s2468-1253(18)30056-6.
    1. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–2063. doi: 10.1016/s0140-6736(14)60220-8.
    1. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–1758. doi: 10.1053/j.gastro.2004.03.018.
    1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. doi: 10.1111/j.1365-2036.2011.04724.x.
    1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. doi: 10.1038/nrgastro.2017.109.
    1. Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25:52–64. doi: 10.3350/cmh.2018.0040.
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. doi: 10.1002/hep.29367.
    1. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol. 2012;56 Suppl 1:S56–S65. doi: 10.1016/s0168-8278(12)60007-5.
    1. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59:1279–1287. doi: 10.1136/gut.2009.192732.
    1. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut. 2004;53:406–412. doi: 10.1136/gut.2003.018770.
    1. Spradling PR, Bulkow L, Teshale EH, Negus S, Homan C, Simons B, McMahon BJ. Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection. J Hepatol. 2014;61:785–791. doi: 10.1016/j.jhep.2014.05.045.
    1. Cheng YL, Wang YJ, Kao WY, Chen PH, Huo TI, Huang YH, Lan KH, Su CW, Chan WL, Lin HC, Lee FY, Wu JC. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One. 2013;8:e72049. doi: 10.1371/journal.pone.0072049.
    1. Lin S, Wang M, Liu Y, Huang J, Wu Y, Zhu Y, Wang X. Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease. Clin Res Hepatol Gastroenterol. 2021;45:101483. doi: 10.1016/j.clinre.2020.06.009.
    1. Huang J, Jing M, Wang C, Wang M, You S, Lin S, Zhu Y. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: A population-based study. J Med Virol. 2020;92:1191–1197. doi: 10.1002/jmv.25621.
    1. Wang B, Li W, Fang H, Zhou H. Hepatitis B virus infection is not associated with fatty liver disease: Evidence from a cohort study and functional analysis. Mol Med Rep. 2019;19:320–326. doi: 10.3892/mmr.2018.9619.
    1. Lv DD, Wang YJ, Wang ML, Chen EQ, Tao YC, Zhang DM, Tang H. Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B. Sci Rep. 2021;11:655. doi: 10.1038/s41598-020-80709-z.
    1. Lin YC, Hsiao ST, Chen JD. Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults. World J Gastroenterol. 2007;13:1805–1810. doi: 10.3748/wjg.v13.i12.1805.
    1. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014;59:2571–2579. doi: 10.1007/s10620-014-3180-9.
    1. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361–1367. doi: 10.1111/j.1440-1746.2011.06801.x.
    1. Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, Chan FK, Chan HL. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540. doi: 10.1016/j.jhep.2011.09.013.
    1. Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology. 2017;65:828–835. doi: 10.1002/hep.28917.
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. doi: 10.1002/hep.28431.
    1. Zhong GC, Wu YL, Hao FB, Rao XW, Yuan XW, Zhao Y, Gong JP. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis. J Viral Hepat. 2018;25:842–852. doi: 10.1111/jvh.12878.
    1. Ding WJ, Wang MM, Wang GS, Shen F, Qin JJ, Fan JG. Thyroid function is associated with non-alcoholic fatty liver disease in chronic hepatitis B-infected subjects. J Gastroenterol Hepatol. 2015;30:1753–1758. doi: 10.1111/jgh.12998.
    1. Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, Bhanthumkomol P, Bandidniyamanon W, Pausawasdi N, Tanwandee T. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int. 2017;37:542–551. doi: 10.1111/Liv.13271.
    1. Zhu L, Jiang J, Zhai X, Baecker A, Peng H, Qian J, Zhou M, Song C, Zhou Y, Xu J, Liu H, Hang D, Hu Z, Shen H, Zhang ZF, Zhu F. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study. Liver Int. 2019;39:70–80. doi: 10.1111/Liv.13933.
    1. Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat. 2012;19:e48–e57. doi: 10.1111/j.1365-2893.2011.01535.x.
    1. Kim CH, Kallman JB, Bai C, Pawloski L, Gewa C, Arsalla A, Sabatella ME, Younossi ZM. Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg. 2010;20:154–160. doi: 10.1007/s11695-008-9549-0.
    1. Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol. 2019;71:1012–1021. doi: 10.1016/j.jhep.2019.06.031.
    1. De Taeye BM, Novitskaya T, McGuinness OP, Gleaves L, Medda M, Covington JW, Vaughan DE. Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab. 2007;293:E713–E725. doi: 10.1152/ajpendo.00194.2007.
    1. Yin Z, Ma T, Lin Y, Lu X, Zhang C, Chen S, Jian Z. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J Cell Biochem. 2018;119:9419–9432. doi: 10.1002/jcb.27259.
    1. Arain SQ, Talpur FN, Channa NA, Ali MS, Afridi HI. Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients. Lipids Health Dis. 2017;16:51. doi: 10.1186/s12944-017-0437-2.
    1. Liu PT, Hwang AC, Chen JD. Combined effects of hepatitis B virus infection and elevated alanine aminotransferase levels on dyslipidemia. Metabolism. 2013;62:220–225. doi: 10.1016/j.metabol.2012.07.022.
    1. Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, Chen CH, Chang KC, Tsai LS, Chen SC, Lu SN. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently. J Gastroenterol Hepatol. 2010;25:1763–1768. doi: 10.1111/j.1440-1746.2010.06300.x.
    1. Li H, Xu QY, Xie Y, Luo JJ, Cao HX, Pan Q. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis. Ann Hepatol. 2021;24:100316. doi: 10.1016/j.aohep.2021.100316.
    1. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–S55. doi: 10.1002/hep.22898.
    1. Huang CY, Lu CW, Liu YL, Chiang CH, Lee LT, Huang KC. Relationship between chronic hepatitis B and metabolic syndrome: A structural equation modeling approach. Obesity (Silver Spring) 2016;24:483–489. doi: 10.1002/oby.21333.
    1. Zhao X, Shah D, Sambamoorthi U. Association between chronic hepatitis B infection and metabolic syndrome. J Diabetes Metab Disord. 2018;17:223–232. doi: 10.1007/s40200-018-0364-4.
    1. Simental-Mendía LE, Rodríguez-Morán M, Gómez-Díaz R, Wacher NH, Rodríguez-Hernández H, Guerrero-Romero F. Insulin resistance is associated with elevated transaminases and low aspartate aminotransferase/alanine aminotransferase ratio in young adults with normal weight. Eur J Gastroenterol Hepatol. 2017;29:435–440. doi: 10.1097/meg.0000000000000811.
    1. Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol. 2008;23:779–782. doi: 10.1111/j.1440-1746.2007.05216.x.
    1. Ye J, Hu X, Wu T, Wu Y, Shao C, Li F, Lin Y, Feng S, Wang W, Zhong B. Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study. Diabetol Metab Syndr. 2019;11:45. doi: 10.1186/s13098-019-0440-z.
    1. Lei S, Chen S, Zhao X, Zhang Y, Cheng K, Zhang X, Wang Z, Sun Y, Wu S, Wang L. Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China. Hepatol Int. 2020;14:743–753. doi: 10.1007/s12072-020-10086-2.
    1. Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, Yuen MF, Seto WK. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800–806. doi: 10.1016/j.jhep.2020.05.040.
    1. Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K. Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. Hepatology. 2020;71:539–548. doi: 10.1002/hep.30857.
    1. Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019;2:e1912565. doi: 10.1001/jamanetworkopen.2019.12565.
    1. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-54. :quiz e39–40. doi: 10.1016/j.cgh.2014.04.014.
    1. Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13:688–694. doi: 10.1007/s12072-019-09995-8.
    1. Brouwer WP, van der Meer AJ, Boonstra A, Pas SD, de Knegt RJ, de Man RA, Hansen BE, ten Kate FJ, Janssen HL. The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. Liver Int. 2015;35:438–447. doi: 10.1111/Liv.12695.
    1. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015; 149: 389-97. :e10. doi: 10.1053/j.gastro.2015.04.043.
    1. Zhu C, Tabas I, Schwabe RF, Pajvani UB. Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis. Nat Rev Gastroenterol Hepatol. 2021;18:131–142. doi: 10.1038/s41575-020-00365-6.
    1. Shi JP, Fan JG, Wu R, Gao XQ, Zhang L, Wang H, Farrell GC. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008;23:1419–1425. doi: 10.1111/j.1440-1746.2008.05531.x.
    1. Wong SW, Chan WK, Mohamed R. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. J Viral Hepat. 2020;27:1297–1305. doi: 10.1111/jvh.13361.
    1. Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, Lai CL, Yuen MF. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44:1071–1079. doi: 10.1111/apt.13804.
    1. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol. 2008;48:829–834. doi: 10.1016/j.jhep.2008.01.016.
    1. Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, Chan HL, To KF, Wong VW. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32:667–676. doi: 10.1111/jgh.13536.
    1. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475. doi: 10.1016/s0140-6736(12)61425-1.
    1. Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis. 2020;24:535–547. doi: 10.1016/j.cld.2020.06.001.
    1. Yu MW, Shih WL, Lin CL, Liu CJ, Jian JW, Tsai KS, Chen CJ. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008;26:5576–5582. doi: 10.1200/jco.2008.16.1075.
    1. Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. Gastroenterology 2017; 153: 1006-1017. :e5. doi: 10.1053/j.gastro.2017.07.001.
    1. Lim CT, Goh GBB, Li H, Lim TK, Leow WQ, Wan WK, Azhar R, Chow WC, Kumar R. Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up. Microbiol Insights. 2020;13:1178636120918878. doi: 10.1177/1178636120918878.
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210.
    1. Tai DI, Tsay PK, Chen WT, Chu CM, Liaw YF. Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age. Am J Gastroenterol. 2010;105:1102–1109. doi: 10.1038/ajg.2009.669.
    1. Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2020;119:1476–1482. doi: 10.1016/j.jfma.2020.05.027.
    1. Chan TT, Chan WK, Wong GL, Chan AW, Nik Mustapha NR, Chan SL, Chong CC, Mahadeva S, Shu SS, Lai PB, Chan HL, Wong VW. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2020;115:867–875. doi: 10.14309/ajg.0000000000000588.
    1. Ceylan B, Arslan F, Batırel A, Fincancı M, Yardımcı C, Fersan E, Paşaoğlu E, Yılmaz M, Mert A. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol. 2016;27:42–46. doi: 10.5152/tjg.2015.150348.
    1. Li J, Le AK, Chaung KT, Henry L, Hoang JK, Cheung R, Nguyen MH. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int. 2020;40:1052–1061. doi: 10.1111/Liv.14415.
    1. Gong L, Liu J, Wang J, Lou GQ, Shi JP. Hepatic Steatosis as a Predictive Factor of Antiviral Effect of Pegylated Interferon Therapy in Patients With Hepatitis B. Transplant Proc. 2015;47:2886–2891. doi: 10.1016/j.transproceed.2015.10.023.
    1. Zhu Y, Yang Q, Lv F, Yu Y. The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis. Gastroenterol Res Pract. 2017;2017:1096406. doi: 10.1155/2017/1096406.
    1. Yao J, Zhou L, Hua X, Kong M, Chen Y, Duan Z. Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study. Nutrition. 2016;32:1206–1210. doi: 10.1016/j.nut.2016.04.001.
    1. Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, Borman MA, Lee SS, Myers RP, Coffin CS. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46:599–604. doi: 10.1111/apt.14218.
    1. Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N NORTE Study Group. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168–180. doi: 10.1007/s00535-020-01750-3.
    1. Sripongpun P, Kim WR, Mannalithara A, Kwong A, Daugherty T, Goel A, Kwo PY. Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2020 doi: 10.1016/j.cgh.2020.11.047.
    1. Donkers JM, Roscam Abbing RLP, van Weeghel M, Levels JHM, Boelen A, Schinkel AH, Oude Elferink RPJ, van de Graaf SFJ. Inhibition of Hepatic Bile Acid Uptake by Myrcludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity. Cell Mol Gastroenterol Hepatol. 2020;10:451–466. doi: 10.1016/j.jcmgh.2020.04.009.
    1. Seto WK, Hui RWH, Mak LY, Fung J, Cheung KS, Liu KSH, Wong DK, Lai CL, Yuen MF. Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. Clin Gastroenterol Hepatol 2018; 16: 575-583. :e2. doi: 10.1016/j.cgh.2017.09.044.
    1. Fu MM, Sun R, Tian ZG, Wei HM. Increased susceptibility to experimental steatohepatitis induced by methionine-choline deficiency in HBs-Tg mice. Hepatobiliary Pancreat Dis Int. 2010;9:513–519.
    1. Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Lammert F, Geier A NAFLD Clinical Study Group. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res. 2017;58:247–255. doi: 10.1194/jlr.P067454.
    1. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018;68:268–279. doi: 10.1016/j.jhep.2017.09.003.
    1. Pan Q, Chen MM, Zhang RN, Wang YQ, Zheng RD, Mi YQ, Liu WB, Shen F, Su Q, Fan JG. PNPLA3 rs1010023 Predisposes Chronic Hepatitis B to Hepatic Steatosis but Improves Insulin Resistance and Glucose Metabolism. J Diabetes Res. 2017;2017:4740124. doi: 10.1155/2017/4740124.
    1. Pan Q, Zhang RN, Wang YQ, Zheng RD, Mi YQ, Liu WB, Shen F, Chen GY, Lu JF, Zhu CY, Zhang SY, Chen YM, Sun WL, Fan JG. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World J Gastroenterol. 2015;21:8605–8614. doi: 10.3748/wjg.v21.i28.8605.
    1. Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MA, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann J, Rahme A, Sheridan D, Booth DR, McLeod D, Powell E, Liddle C, Douglas MW, van der Poorten D, George J International Liver Disease Genetics Consortium. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64:34–46. doi: 10.1002/hep.28475.
    1. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, Yang US, Yu DY, Cheong J. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007;132:1955–1967. doi: 10.1053/j.gastro.2007.03.039.
    1. Wu YL, Peng XE, Zhu YB, Yan XL, Chen WN, Lin X. Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein. J Virol. 2016;90:1729–1740. doi: 10.1128/jvi.02604-15.
    1. Zhang S, Gao S, Zhao M, Liu Y, Bu Y, Jiang Q, Zhao Q, Ye L, Zhang X. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein. Cancer Lett. 2017;392:94–104. doi: 10.1016/j.canlet.2017.02.003.
    1. Hsu CS, Liu WL, Chao YC, Lin HH, Tseng TC, Wang CC, Chen DS, Kao JH. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. Hepatol Int. 2015;9:231–242. doi: 10.1007/s12072-015-9616-2.
    1. Bedossa P FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–575. doi: 10.1002/hep.27173.
    1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701.
    1. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699. doi: 10.1016/0168-8278(95)80226-6.
    1. and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20:15–20.
    1. Zhuang Z, Qu H, Yang W, Liu J, Wang F, Liu Y, Ding J, Shi J. Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method. Ann Hepatol. 2020;19:313–319. doi: 10.1016/j.aohep.2019.11.003.
    1. Worland T, Apostolov R, Asadi K, Leung C. Hepatitis B virus activity is not associated with degree of liver steatosis in patients with hepatitis B-related chronic liver disease. Liver Int. 2020;40:1500–1502. doi: 10.1111/Liv.14344.
    1. U S. Food and Drug Administration (FDA) Guidance for Industry. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). 2018. [cited5 February2021] Available from: .
    1. Anania FA, Dimick-Santos L, Mehta R, Toerner J, Beitz J. Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration. Hepatology. 2021;73:2023–2027. doi: 10.1002/hep.31687.
    1. Eslam M, Sanyal AJ, George J. Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology. 2019;157:590–593. doi: 10.1053/j.gastro.2019.05.064.
    1. Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919. doi: 10.1007/s12072-020-10094-2.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi